GALT•benzinga•
Galectin Therapeutics Announces NAVIGATE Trial Results: Belapectin Shows 49.3% Reduction In Varices For Completer Patients In MASH Cirrhosis, Composite Endpoint Not Met
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 18, 2025 by benzinga